2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2662

Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome
Abstract Number: 621

Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
Abstract Number: 981

Effectiveness of a Six-Week Hand Osteoarthritis Program in a Primary Care Setting
Abstract Number: 985

Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool with or without a Health Educator for Knowledge of RA Risk Factors
Abstract Number: 1337

Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
Abstract Number: 3206

Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
Abstract Number: 954

Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Abstract Number: 2324

Effects of 12 Weeks Low-Intensity Blood-Flow Restricted Resistance Training on Knee Extensor Strength in Patients with Sporadic Inclusion Body Myositis
Abstract Number: 378

Effects of a Natural Product Containing Specialized Pro-Resolving Mediators in Subjects with OA, RA, or Other Chronic Inflammatory Conditions in a Multi-Clinic Case Series
Abstract Number: 2084

Effects of a Web-Based Patient Decision Aid on Biologics for Rheumatoid Arthritis: A Proof-of-Concept Study
Abstract Number: 9

Effects of Alcohol Consumption on the Severity of Inflammation in Hand and Foot Joints Detected with MR Imaging
Abstract Number: 1158

Effects of an Educational Program Using Treat to Target Strategy in Korean Patients with Rheumatoid Arthritis
Abstract Number: 1748

Effects of Anti-High Mobility Group Box 1 Antibody for MRL/Lpr lupus-Prone Mice
Abstract Number: 2632

Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis
Abstract Number: 2444

Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].